Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 18 studies | 46% ± 19% | |
lung | 17 studies | 46% ± 17% | |
brain | 12 studies | 29% ± 10% | |
intestine | 11 studies | 41% ± 22% | |
eye | 9 studies | 32% ± 15% | |
kidney | 8 studies | 34% ± 12% | |
bone marrow | 6 studies | 40% ± 25% | |
lymph node | 6 studies | 45% ± 17% | |
uterus | 5 studies | 54% ± 21% | |
liver | 5 studies | 46% ± 18% | |
pancreas | 4 studies | 61% ± 18% | |
breast | 4 studies | 51% ± 11% | |
placenta | 3 studies | 66% ± 6% | |
prostate | 3 studies | 57% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 11225.73 | 459 / 459 | 100% | 331.80 | 1118 / 1118 |
esophagus | 100% | 11748.43 | 1445 / 1445 | 100% | 260.47 | 183 / 183 |
intestine | 100% | 11870.11 | 966 / 966 | 100% | 276.95 | 527 / 527 |
lung | 100% | 11506.51 | 578 / 578 | 100% | 254.28 | 1155 / 1155 |
ovary | 100% | 12974.29 | 180 / 180 | 100% | 234.72 | 430 / 430 |
pancreas | 100% | 7389.85 | 328 / 328 | 100% | 206.88 | 178 / 178 |
stomach | 100% | 8776.11 | 359 / 359 | 100% | 238.12 | 286 / 286 |
brain | 100% | 10220.90 | 2641 / 2642 | 100% | 252.11 | 705 / 705 |
thymus | 100% | 10876.25 | 653 / 653 | 100% | 254.55 | 604 / 605 |
prostate | 100% | 10421.06 | 245 / 245 | 100% | 240.97 | 501 / 502 |
uterus | 100% | 12654.84 | 170 / 170 | 100% | 316.97 | 458 / 459 |
bladder | 100% | 12717.14 | 21 / 21 | 100% | 267.37 | 502 / 504 |
kidney | 100% | 9693.60 | 89 / 89 | 99% | 177.15 | 892 / 901 |
skin | 100% | 15519.10 | 1809 / 1809 | 99% | 250.88 | 467 / 472 |
liver | 100% | 4872.57 | 226 / 226 | 95% | 111.09 | 384 / 406 |
adrenal gland | 100% | 10261.92 | 258 / 258 | 93% | 125.88 | 215 / 230 |
adipose | 100% | 11330.58 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 10295.87 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 399.29 | 29 / 29 |
muscle | 100% | 9763.48 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 11710.77 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 307.07 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 150.17 | 1 / 1 |
heart | 98% | 7303.39 | 841 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 223.44 | 78 / 80 |
peripheral blood | 91% | 11581.47 | 842 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006260 | Biological process | DNA replication |
GO_0006334 | Biological process | nucleosome assembly |
GO_0006337 | Biological process | nucleosome disassembly |
GO_0043524 | Biological process | negative regulation of neuron apoptotic process |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0005811 | Cellular component | lipid droplet |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0042393 | Molecular function | histone binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0004864 | Molecular function | protein phosphatase inhibitor activity |
GO_0019888 | Molecular function | protein phosphatase regulator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | SET |
Protein name | Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I) SET nuclear proto-oncogene SET (cDNA FLJ51749, highly similar to Protein SET) |
Synonyms | hCG_40357 |
Description | FUNCTION: Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone chaperoning. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins; however, isoform 2 specific activity is higher. . |
Accessions | ENST00000372692.8 [Q01105-1] Q5VXV3 Q01105 A0A0C4DFV9 ENST00000691158.1 ENST00000686568.1 A0A8J8YYJ1 A0A8I5KTZ2 ENST00000372686.6 ENST00000322030.13 [Q01105-2] ENST00000372688.9 ENST00000409104.7 [Q01105-4] ENST00000686840.1 [Q01105-1] A0A8I5KS71 |